###begin article-title 0
IGF1 Is a Common Target Gene of Ewing's Sarcoma Fusion Proteins in Mesenchymal Progenitor Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: IS LC. Performed the experiments: LC NR NW DS. Analyzed the data: IS PP LC NR MLS DS. Contributed reagents/materials/analysis tools: VK PP DS. Wrote the paper: IS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 254 257 <span type="species:ncbi:12672?0.125">FEV</span>
The EWS-FLI-1 fusion protein is associated with 85-90% of Ewing's sarcoma family tumors (ESFT), the remaining 10-15% of cases expressing chimeric genes encoding EWS or FUS fused to one of several ets transcription factor family members, including ERG-1, FEV, ETV1 and ETV6. ESFT are dependent on insulin-like growth factor-1 (IGF-1) for growth and survival and recent evidence suggests that mesenchymal progenitor/stem cells constitute a candidate ESFT origin.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
To address the functional relatedness between ESFT-associated fusion proteins, we compared mouse progenitor cell (MPC) permissiveness for EWS-FLI-1, EWS-ERG and FUS-ERG expression and assessed the corresponding expression profile changes. Whereas all MPC isolates tested could stably express EWS-FLI-1, only some sustained stable EWS-ERG expression and none could express FUS-ERG for more than 3-5 days. Only 14% and 4% of the total number of genes that were respectively induced and repressed in MPCs by the three fusion proteins were shared. However, all three fusion proteins, but neither FLI-1 nor ERG-1 alone, activated the IGF1 promoter and induced IGF1 expression.
###end p 5
###begin title 6
Conclusion/Significance
###end title 6
###begin p 7
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
Whereas expression of different ESFT-associated fusion proteins may require distinct cellular microenvironments and induce transcriptome changes of limited similarity, IGF1 induction may provide one common mechanism for their implication in ESFT pathogenesis.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Helman1">[1]</xref>
###xml 164 167 164 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi1">[2]</xref>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Delattre1">[3]</xref>
###xml 530 533 530 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Helman1">[1]</xref>
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi2">[4]</xref>
###xml 740 743 740 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Helman1">[1]</xref>
###xml 745 748 745 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi2">[4]</xref>
###xml 495 498 <span type="species:ncbi:12672?0.125">FEV</span>
Ewing's sarcoma family tumors are associated with non-random chromosomal translocations that generate fusion genes which encode aberrant transcription factors [1], [2]. The most common chromosomal translocation, associated with 85% of ESFTs is t(22;11)(q24;q12 ), which generates the EWS-FLI-1 fusion [3]. The t(21;22)(q22;q12) translocation is associated with about 10% of tumors and leads to EWS-ERG formation, whereas the remaining 1-5% of ESFT bear translocations that generate FUS-ERG, EWS-FEV, EWS-ETV1 and EWS-ETV4 fusions [1], [4]. In all cases, the transactivation domain of one of the TET (TLS/FUS, EWS, TAFII68) family of proteins is fused to the DNA binding domain-containing region of an ets transcription factor family member [1], [4].
###end p 9
###begin p 10
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Thompson1">[5]</xref>
###xml 386 389 386 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Deneen1">[6]</xref>
###xml 391 394 391 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Lessnick1">[7]</xref>
###xml 736 739 736 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 861 870 861 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS-FLI-1</sup>
###xml 861 870 861 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>EWS-FLI-1</sup></italic>
###xml 951 954 951 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 1095 1101 1095 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1,</italic>
###xml 1158 1161 1158 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 1195 1200 1195 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 358 363 <span type="species:ncbi:9606">human</span>
###xml 368 373 <span type="species:ncbi:10090">mouse</span>
The fusion proteins associated with ESFT are believed to provide the oncogenic stimulus that transforms primary cells, at least in part by altering their transcriptome. In NIH 3T3 cells, different ESFT-associated fusion genes have been observed to induce a similar tumor phenotype [5]. However, EWS-FLI-1 induces an oncogenic stress-type response in primary human and mouse fibroblasts [6], [7], suggesting that a distinctly permissive cellular environment may be required for EWS-FLI-1-mediated oncogenesis. Recent evidence indicates that primary bone marrow-derived MPCs are permissive for EWS-FLI-1 expression as well as its transforming effects and that EWS-FLI-1 expression may constitute the initiating event in ESFT pathogenesis [8]. In contrast to other primary or transformed heterologous cells transduced with EWS-FLI-1, MPCs expressing EWS-FLI-1 (MPCEWS-FLI-1) displayed a transcriptome consistent with survival, proliferation and invasion [8]. Among potentially relevant genes found to be induced in MPCs but not in other primary cells infected with EWS-FLI-1-containing vectors was IGF-1, which constitutes a key growth factor for ESFT survival [8]. These observations suggest that IGF-1 may be an EWS-FLI-1 target in a permissive cellular context that may constitute an origin of ESFT.
###end p 10
###begin p 11
###xml 268 271 268 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-May1">[9]</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Zwerner1">[10]</xref>
###xml 451 468 451 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS-FLI1, EWS-ERG</italic>
###xml 473 480 473 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-ERG</italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLI1</italic>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERG1</italic>
###xml 664 671 664 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-ERG</italic>
###xml 730 734 730 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Shing1">[11]</xref>
###xml 1023 1028 1023 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1.</italic>
###xml 1074 1078 1074 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
Most studies on ESFT fusion proteins have been conducted on EWS-FLI-1, given that the frequency of its association with ESFT is by far the highest. Several of these studies have shown that the target gene repertoire of EWS-FLI-1 varies according to the host cell type [9], [10]. To determine whether EWS-FLI-1 and other ESFT-associated fusion proteins trigger similar responses in cells from which ESFT are believed to originate, we stably introduced EWS-FLI1, EWS-ERG and FUS-ERG into MPC and addressed the corresponding transcription profile changes. We compared these changes to those induced by FLI1 and ERG1 alone as well as to those induced by an isoform of FUS-ERG associated with acute myeloid leukemia (AML) but not ESFT [11]. Our results show that MPCs display differential permissiveness for EWS-FLI-1, EWS-ERG and FUS-ERG and that among the gene expression changes induced by the three fusion proteins only a limited fraction are shared. One of the genes observed to be induced by all three fusion proteins was IGF1. In the present work we provide evidence that IGF1 is a direct target gene of ESFT fusion proteins.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Expression of ESFT fusion proteins in mesenchymal progenitor cells
###end title 13
###begin p 14
###xml 20 37 20 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS-FLI1, EWS-ERG</italic>
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-ERG</italic>
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-ERG</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLI1</italic>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERG1</italic>
###xml 159 180 159 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">materials and methods</xref>
###xml 243 251 243 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g001">Figure 1</xref>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS-FLI1</italic>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Welford1">[12]</xref>
###xml 95 100 <span type="species:ncbi:9606">human</span>
The Ewing's sarcoma EWS-FLI1, EWS-ERG and FUS-ERG fusion genes, the AML FUS-ERG fusion and the human FLI1 and ERG1 genes were RT-PCR amplified as described in materials and methods. A schematic representation of all the constructs is shown in Figure 1. An EWS-FLI1 mutant encoding the R340N mutation in the DNA binding domain of FLI-1 was generated to serve as a control for DNA binding-dependent versus DNA binding-independent effects. The R340N mutant (DNA-binding mutant, DBDM) has been shown to conserve some degree of transforming capacity in NIH3T3 fibroblasts despite lacking DNA binding activity [12].
###end p 14
###begin title 15
###xml 101 106 <span type="species:ncbi:9606">human</span>
Schematic representation of EWS-FLI-1, EWS-ERG, FUS-ERG (AML) and FUS-ERG (ESFT) fusion proteins and human ERG-1 and FLI-1 proteins.
###end title 15
###begin p 16
Amino acid sequences at the breackpoints of each chimera are annotated and breakpoints on ERG-1 and FLI-1 are indicated by arrows.
###end p 16
###begin p 17
###xml 748 756 748 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g002">Figure 2</xref>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Three independently isolated C57Bl6 mouse MPC populations were derived from the bone marrow, and three to four replicate infections were performed for each construct. Thus, the same MPC populations were used to test the expression and effect of each fusion and wt protein, eliminating the possibility that any difference in the effects of the proteins might reflect differences among the primary MPC batches. Expression of all three fusion proteins induced mild but readily detectable morphological changes of the MPCs, characterized by loss of the elongated spindle shape and rounding. By contrast, cells expressing the DNA binding mutant of EWS-FLI-1 maintained the characteristic MPC spindle shape as did cells expressing FLI-1 and ERG-1 alone (Figure 2). No change in the expression of mesenchymal stem cell markers, as assessed by FACS analysis, was observed in any of these populations (data not shown).
###end p 17
###begin title 18
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Phenotype of mouse MPCs infected with EWS-FLI-1, EWS-FLI-1 R340N mutant, EWS-ERG, FUS-ERG ESFT, FUS-ERG AML, ERG-1, FLI-1 or an empty pMSCV puro vector.
###end title 18
###begin p 19
Images were taken 3 days after infection (200X magnification).
###end p 19
###begin p 20
###xml 191 200 191 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g003">Figure 3A</xref>
###xml 459 468 459 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s001">Figure S1</xref>
###xml 611 619 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g003">Figure 3</xref>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g003">Figure 3</xref>
###xml 844 853 844 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s001">Figure S1</xref>
###xml 1218 1226 1218 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g004">Figure 4</xref>
###xml 1379 1388 1379 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g004">figure 4A</xref>
###xml 1708 1717 1708 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g004">figure 4B</xref>
###xml 1869 1872 1869 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 1890 1893 1890 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERG</italic>
###xml 2017 2020 2017 2020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 2049 2052 2049 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERG</italic>
###xml 2125 2128 2125 2128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS</italic>
###xml 2165 2168 2165 2168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERG</italic>
Expression of the fusion and wild type proteins was tested by Western blot analysis. All of the fusion proteins as well as FLI-1 and ERG-1 were readily detected 36 hours following infection (Figure 3A). Densitometric analysis revealed that EWS-FLI-1, EWS-ERG and the ESFT-associated FUS-ERG isoform were expressed at comparable levels, whereas the DBDM, FLI-1, ERG-1 and the AML-associated FUS-ERG isoform displayed a 1.5 to 2.5 fold higher expression level (Figure S1). Expression of wild type FLI-1 and ERG-1, as well as that of the DBDM was stably maintained by MPCs infected with the corresponding viruses (Figure 3 B); EWS-FLI-1 protein expression was also stably maintained by MPCs, but at a 4-, 2- and 7 fold lower level than the DBDM and the FLI-1 and ERG-1 proteins, respectively, as assessed by densitometric analysis (Figure 3 B and Figure S1). Comparable expression levels of each of these proteins were observed in independently infected cells derived from the same primary population and in different MPC populations (data not shown). However, the same MPC populations displayed variable ability to maintain EWS-ERG expression and were unable to stably express either of the two FUS-ERG fusion proteins (Figure 4 and data not shown). The EWS-ERG fusion protein was maintained beyond 14 days of culture and selection in only one out of three MPC populations tested (figure 4A, lanes 3, 6, 9). Both genomic DNA and total RNA from cells that had lost EWS-ERG protein expression tested positive for the presence of EWS-ERG by PCR or RT-PCR using EWS-ERG specific primers. In some samples, RT-PCR analysis showed that loss of protein expression was accompanied by non-random EWS-ERG RNA processing (figure 4B, lane 4), reflected by the presence of two distinct transcripts of about 250 and 500 bp. PCR-amplification using primers complementary to the 5'end of EWS and the 3'end of ERG and subsequent sequence analysis of the amplicons revealed that the lower band was composed of the initial 5' 175 bases of EWS fused to the 3' 57 bases of ERG and the V5 tag. The higher band consisted of the 5' 333 coding bases of EWS fused to the 3' 139 coding bases of ERG and the V5 tag. In both cases the Ewing's sarcoma breakpoint was lost and translation showed no open reading frame (data not shown). No deamination was observed within the sequence suggesting the absence of RNA editing, and no point mutations were found in the EWS/ERG sequence.
###end p 20
###begin title 21
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
###xml 28 33 <span type="species:ncbi:9606">human</span>
Expression in mouse MPCs of human FLI-1 and ERG-1 , ESFT-associated fusion proteins EWS-FLI-1 (EF), EWS-ERG (EE) and FUS-ERG (FE), the AML-associated FUS-ERG fusion protein variant and the EWS-FLI-1 R340N DBD mutant.
###end title 21
###begin p 22
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 497 502 <span type="species:ncbi:10090">mouse</span>
###xml 554 559 <span type="species:ncbi:10090">mouse</span>
###xml 565 570 <span type="species:ncbi:9606">human</span>
###xml 663 667 <span type="species:ncbi:9925">goat</span>
###xml 673 678 <span type="species:ncbi:10090">mouse</span>
###xml 695 700 <span type="species:ncbi:10090">mouse</span>
Mouse MPCs were infected with human ERG-1 (A and B lane 4), human FLI-1 (A and B, lane 2), EWS-FLI-1 (A and B, lanes 7), EWS-FLI-1 R340N DBD mutant (A and B, lanes 8), EWS-ERG (A and B, lanes 6), FUS-ERG ESFT (lane 10), FUS-ERG AML (lane 11), or an empty pMSCV puro vector (A, lanes 1,3,5,9; B lanes 1, 3, 5). Cells were harvested 36 hours after the infection (A) or selected in 1.5 microg/ml puromycin for a period of 14 days (B). Protein expression was assessed by western blot analysis using a mouse anti v5 epitope (A, lanes 3-11; B, lanes 3-8) or a mouse anti human FLI-1 monoclonal antibody (A and B lanes 1-2). The secondary antibody was an HRP-conjugated goat anti mouse IgG. Monoclonal mouse anti-actin antibody was used as a loading control. With the exception of EWS-ERG in selected cells (B, lane 6), bands are representative of expression levels obtained in 3 independent MPC populations.
###end p 22
###begin title 23
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
Variability of EWS-ERG expression in mouse MPCs.
###end title 23
###begin p 24
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 411 416 <span type="species:ncbi:10090">mouse</span>
###xml 443 447 <span type="species:ncbi:9925">goat</span>
###xml 453 458 <span type="species:ncbi:10090">mouse</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
###xml 977 982 <span type="species:ncbi:10090">mouse</span>
A) Western blot analysis: three independent MPCs populations were infected with human ERG-1 (lanes 2, 5 and 8), EWS-ERG (lanes 3, 6 and 9) or an empty pMSCV puro vector (lanes 1,4 and 7). After confirming ERG-1 and EWS-ERG expression at the protein level 36 hours following infection (data not shown), cells were selected with 1.5 microg/ml puromycin for 14 days, and protein expression was re-assessed using a mouse anti v5 epitope mAb and a goat anti mouse-HRP conjugated antibody. Monoclonal mouse anti-actin was used as a loading control. (B) RT-PCR analysis of EWS-ERG infected MPC populations. RNA was extracted from puromycin-selected MPCs populations expressing (lanes 1 and 6) or not (lanes 2 and 4) EWS-ERG protein and from puromycin-selected MPC populations infected with an empty pMSCV puro vector (lanes 3 and 7). RT-PCR was performed using primers complementary to the 5'end of EWS and at the 3'end of ERG. A control lacking RT was included (lane 5) as well as a mouse beta-actin amplification RNA control. (C) Genomic DNA analysis of EWS-ERG infected MPC populations. Lanes1 and 3: puromycin-selected MPC populations lacking EWS/ ERG protein (A lane 3) and showing degraded EWS-ERG RNA (B lane 4). Lanes 2 and 4: puromycin-selected MPC populations infected with an empty pMSCV puro vector. PCR was performed using primers either at the 5'end of EWS and at the 3'end of ERG-1 (lanes 3 and 4) or primers located on the pMSCV vector (lanes 1 and 2). D) Genomic DNA analysis of FUS-ERG infected MPCs populations. Genomic DNA was extracted from puromycin-selected MPCs populations infected with ESFT-associated FUS-ERG (lane 3), AML-associated FUS-ERG (lane 2) or an empty pMSCV puro vector (lane 1). PCR was performed using primers complementary to the 5'end of EWS and to the 3'end of FUS.
###end p 24
###begin p 25
###xml 183 192 183 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g004">figure 4D</xref>
Expression of both FUS-ERG fusion proteins was limited to no more than 3-5 days. Cells surviving puromycin selection tested positive for FUS-ERG DNA integration into the host genome (figure 4D) but were negative for FUS-ERG RNA expression.
###end p 25
###begin p 26
###xml 21 30 21 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s002">Figure S2</xref>
Cell cycle analysis (Figure S2) showed that 36 hours following infection, prior to puromycin selection, only a small fraction of cells underwent apoptosis, with no significant difference among the different fusion gene-containining vector-infected cells (data not shown). At later time points, under puromycin selection, all of the populations displayed higher fractions of apoptotic cells. However, there was little difference in the apoptotic cell fractions among populations expressing the different fusion genes. In fact, the highest fraction of apoptotic cells seemed to be found in the EWS-FLI-1 expressing cell population, suggesting that apoptosis was not the main cause of the loss of EWS-ERG and FUS-ERG protein expression.
###end p 26
###begin title 27
Gene expression profiles of MPCs containing ESFT fusion proteins, FLI-1 and ERG-1 display limited similarity
###end title 27
###begin p 28
###xml 779 787 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s003">Table S1</xref>
###xml 789 797 789 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
Transcriptional changes were analysed 36 hours and 4 days following infection, when expression of all of the fusion proteins and that of the corresponding wild type ets family proteins was comparable. No significant difference in the gene expression profile induced by the various fusion genes at 36 hours and 4 days was observed (data not shown). The number of genes observed to be induced and repressed differed among cells expressing the three fusion proteins, with a higher number of genes being affected by EWS-FLI-1 and FUS-ERG than by EWS-ERG. Using a 5% false discovery rate, cells expressing EWS-ERG displayed 67 repressed and 144 induced genes, whereas EWS-FLI-1 and FUS-ERG expressing cells had 199 and 172 repressed and 250 and 208 induced transcripts, respectively (Table S1, Figure 5).
###end p 28
###begin title 29
Venn diagrams indicating the extent of overlap of the transcription profiles of MPCs expressing the three ESFT- associated fusion proteins, ERG-1, FLI-1, the EWS-FLI-1 R340N mutant and the AML-associated FUS-ERG fusion protein.
###end title 29
###begin p 30
A white asterisk marks the areas where Igf1 is commonly present.
###end p 30
###begin p 31
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Lessnick2">[13]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-May2">[14]</xref>
###xml 257 265 257 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
###xml 702 710 678 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s003">Table S1</xref>
###xml 715 723 691 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
###xml 854 862 830 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
###xml 867 875 843 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s003">Table S1</xref>
###xml 1587 1595 1563 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
Consistent with the notion that a predominantly gene expression inducing transcriptional activity is associated with ESFT fusions [13], [14], pairwise comparison revealed greater similarity among the induced than among the repressed transcript repertoires (Figure 5). Thus, of all of the genes induced in cells infected with EWS-FLI-1 and EWS-ERG retroviruses, approximately40% were shared whereas only approximately13% of those that were repressed were common. EWS-ERG and FUS-ERG expressing cells shared about 21% of the induced but less than 12% of repressed transcript repertoire, similar to EWS-FLI-1 and FUS-ERG expressing cells that shared 22% of their induced and 10% of their repressed genes (Table S1 and Figure 5). Fifty-seven induced (14% of the total) and 13 repressed (4% of the total) transcripts were common to all three fusion proteins (Figure 5 and Table S1). The same comparison revealed somewhat greater similarity between EWS-FLI-1 and EWS-ERG induced genes than between genes induced by either fusion and those induced by FUS-ERG, suggesting a potentially important role of the N-terminal portion of the fusions in target gene selection. In contrast to the limited but nevertheless significant overlap of induced and repressed transcripts in response to the three fusion proteins, ERG-1 and FLI-1 shared very few common targets in MPCs. Whereas ERG-1 induced 122 and repressed 329 transcripts, and FLI-1 induced 290 and repressed 169 transcripts, only 14 of the induced (3.5%) and 8 of the repressed transcripts (1.6%) were common to the two transcription factors (Figure 5).
###end p 31
###begin p 32
###xml 149 157 149 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
Similarity between the effects of FLI-1 and ERG-1 and those of their corresponding fusion proteins was also limited to a restricted number of genes (Figure 5). Thus, about 20% of all of the genes induced and repressed by EWS-ERG were also induced and repressed by ERG-1 alone and less than 8% of genes induced and repressed by EWS-FLI-1 were induced and repressed by FLI-1 alone.
###end p 32
###begin p 33
###xml 652 660 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
The role of the DNA binding domain in the transcriptional activity of EWS-FLI-1 fusion protein was addressed by comparing the transcriptional activity of wt EWS-FLI-1 with that of the DBDM. The EWS-FLI-1 DBDM induced 98 and repressed 167 transcripts in MPCs compared to, respectively, 250 induced and 199 repressed transcripts by wt EWS-FLI-1, suggesting that impairment of EWS-FLI-1 DNA binding affects the transcriptional activation capacity of the fusion more strongly than its transcriptional repression capacity. Pairwise comparison revealed that only 65 out of a total of 649 (approximately10%) genes that were induced and repressed were shared (Figure 5).
###end p 33
###begin p 34
###xml 344 352 344 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g005">Figure 5</xref>
###xml 354 362 354 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s003">Table S1</xref>
Finally, comparison between the effects on MPCs of FUS-ERG fusions found in ESFT and AML revealed a similar number of induced and repressed transcripts. Of the total induced transcripts by the two fusion proteins, about 34% were common whereas about 22% of all of the repressed transcripts were shared between cells expressing the two fusions (Figure 5, Table S1).
###end p 34
###begin title 35
Distinct and common candidate target genes of ESFT fusion proteins and their component ets family members
###end title 35
###begin p 36
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s004">Table S2</xref>
###xml 374 382 374 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002634.s005">Table S3</xref>
###xml 385 395 385 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHH, PODXL</italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT119</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH5</italic>
###xml 523 530 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t001">Table 1</xref>
###xml 546 581 546 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CITED1, SFRP4, IGF1, IGFBP5, IGFBP3</italic>
###xml 586 590 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENO3</italic>
###xml 726 733 726 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t001">Table 1</xref>
###xml 767 787 767 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DCN, MT2, DKK3, DKK2</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
Expression of fifteen of the genes that were found to be significantly up- or down-regulated in MPC expressing EWS-FLI1, EWS-ERG and FUS-ERG was validated by quantitative real-time PCR in the corresponding cells as well as in FLI-1 and ERG-1 expressing counterparts (a complete list of up- and downregulated genes is provided in Table S2, whereas shared genes are listed in Table S3). DHH, PODXL, KRT119 and CDH5 were up-regulated in FLI-1 and ERG-1-expressing cells as well as in all three fusion protein expressing MPCs (Table 1). By contrast, CITED1, SFRP4, IGF1, IGFBP5, IGFBP3 and ENO3 were among genes that were upregulated in all three fusion protein containing cells but not in cells expressing FLI-1 and ERG-1 alone (Table 1). Several other genes, including DCN, MT2, DKK3, DKK2 and MMP3 displayed movement in one or two fusion protein containing cells but not in FLI-1 and ERG-1 retrovirus-infected cells.
###end p 36
###begin title 37
Real time PCR validation of ESFT fusion protein- and wild type FLI-1 and ERG-1-induced and repressed genes 36 hours following infection
###end title 37
###begin p 38
The indicated fold increase or decrease (-) and the corresponding standard deviation are representative of three independent experiments. Lower than two-fold increases or decreases in absolute value are indicated.as <I 2 I
###end p 38
###begin p 39
###xml 116 137 116 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3, PODXL, KRT119</italic>
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH5</italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t002">Table 2</xref>
###xml 288 305 288 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHH, IGF1, IGFBP5</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENO3</italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CITED1</italic>
###xml 471 478 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t002">Table 2</xref>
Comparison of the expression of these same genes in cells expressing EWS-FLI-1 and the EWS-FLI-1 DBDM revealed that IGFBP3, PODXL, KRT119 and CDH5 were induced in both cell types, albeit substantially more strongly in wt EWS-FLI-1 expressors for all except IGFBP3 (Table 2). By contrast, DHH, IGF1, IGFBP5 and ENO3 were upregulated in wt EWS-FLI-1 expressing cells only. CITED1 was upregulated in both but more than 150 times more strongly in EWS-FLI-1 expressing cells (Table 2).
###end p 39
###begin title 40
Real time PCR validation of EWS-FLI-1- and EWS-FLI-1 R340N-induced and repressed genes 36 hours following infection
###end title 40
###begin p 41
The indicated fold increase or decrease (-) and the corresponding standard deviation are representative of three independent experiments. Lower than two-fold increases or decreases in absolute value are indicated.as <I 2 I
###end p 41
###begin p 42
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHH</italic>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 300 307 300 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t003">Table 3</xref>
When the effects of the two FUS-ERG fusions in MPCs were compared, all of the genes tested displayed movement in the same direction. The only difference was that the degree of induction of each gene was 1.25 (DHH) to more than 10 (IGFBP3) times greater in cells expressing the AML-associated fusion (Table 3). It is conceivable that the stronger induction associated with the AML than with the ESFT fusion is a reflection of the higher expression level of the AML fusion protein that appears to be tolerated in MPCs.
###end p 42
###begin title 43
Real time PCR validation of FUS-ERG fusion protein-induced and repressed genes 36 hours following infection
###end title 43
###begin p 44
The indicated fold increase or decrease (-) and the corresponding standard deviation are representative of three independent experiments. Lower than two-fold increases or decreases in absolute value are indicated as <I 2 I
###end p 44
###begin p 45
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CITED1</italic>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Baird1">[15]</xref>
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHH</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SFRP4</italic>
###xml 284 297 284 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PODXL, KRT119</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH5</italic>
###xml 580 584 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Welford1">[12]</xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Among the other putative gene targets, CITED1, which is a major discriminator of human ESFT with respect to other sarcomas [15] was strongly induced by the fusion proteins but only weakly by the DBDM. DHH and SFRP4 were both induced by wt fusion proteins but not by the DBDM, whereas PODXL, KRT119 and CDH5 were induced both by FLI-1 and ERG-1 alone and by the EWS-FLI-1 DBDM. These observations suggest that the DBDM conserves some transcriptional or transcription co-factor activity, consistent with the report that it maintains a degree of transforming ability in NIH3T3 cells [12].
###end p 45
###begin title 46
EWS-FLI-1 recognizes the IGF1 promoter
###end title 46
###begin p 47
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 407 416 407 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g006">Figure 6A</xref>
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Alfieri1">[16]</xref>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 755 759 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 983 987 983 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
###xml 385 391 <span type="species:ncbi:10090">murine</span>
###xml 499 505 <span type="species:ncbi:10090">murine</span>
###xml 594 600 <span type="species:ncbi:10090">murine</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
To address the interaction between EWS-FLI-1 and the IGF1 promoter in vivo, chromatin immunoprecipitates (ChIP) from lysates of mouse MPCs expressing EWS-FLI-1, the DBDM and the empty vector were subjected to quantitative RT-PCR using primers specific for the region stretching from -2754 nucleotides to -2683 nucleotides upstream of the exon 1 start codon (ENSMUSE00000369489) of the murine IGF1 promoter (Figure 6A). This 70 bp stretch corresponds to the sequence annotated as -408 to -338 of the murine IGF1 promoter in a recent report by Alfieri et al. [16] and is included in the putative murine IGF1 promoter region GXP_41004 defined by the Genomatix () genome annotation tool "Eldorado". This region shows the highest similarity (96%) to the human IGF1 promoter region GXP_79580 and, by Genomatix analysis, is suggested to contain several potential trancription factor binding sites including ets binding sites. Relative to empty vector-expressing cells, a 5 fold increase in IGF1 promoter occupancy by the fusion protein was observed in ChIP assays directed against the anti-V5 epitope on the EWS/FLI-1 fusion protein.
###end p 47
###begin title 48
###xml 76 82 <span type="species:ncbi:10090">murine</span>
In vivo interaction of EWS-FLI-1 with the region from -2754 to -2683 of the murine IGF1 promoter.
###end title 48
###begin p 49
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 195 201 <span type="species:ncbi:10090">murine</span>
###xml 440 446 <span type="species:ncbi:10090">murine</span>
A) Quantitative RT-PCR analysis was performed on chromatin immunoprecipitates obtained from mouse MPCs expressing EWS-FLI-1, EWS-FLI-1 R340N mutant or an empty pMSCV vector. Primers specific for murine GAPDH DNA were used as input DNA control. Error bars reflect results of triplicate experiments. (B) IGF1 mRNA induction by EWS-FLI-1 and EWS-FLI-1 R340N in the MPCs used for the ChIP experiments. Quantitative RT-PCR was performed using a murine IGF1 TaqMAN probe (applied biosystems).
###end p 49
###begin p 50
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 114 123 114 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g006">Figure 6B</xref>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g006">Figure 6</xref>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
EWS-FLI-1 expressing cells displayed a 9 fold increase in IGF1 message as measured by quantitative real time PCR (Figure 6B). No IGF1 promoter occupancy was observed in chromatin immunoprecipitates from the DBDM expressing cells, which also displayed no induction of IGF1 transcripts (Figure 6). Similarly, no enrichment was observed using a second set of primers amplifying a region located about 14000 bp upstream of the IGF1 exon 1 start codon containing no putative ets binding sites (data not shown).
###end p 50
###begin title 51
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Modulation of human IGF1 promoter activity in human mesenchymal stem cells
###end title 51
###begin p 52
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 336 344 336 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EWS-FLI1</italic>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi4">[17]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Tirode1">[18]</xref>
###xml 743 747 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Wynes1">[19]</xref>
###xml 1203 1207 1203 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Mittanck1">[20]</xref>
###xml 1398 1402 1398 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 45 51 <span type="species:ncbi:10090">murine</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
The effect of the various fusion proteins on murine IGF-1 promoter activity was tested in MPCs using a luciferase reporter assay, but a high background rendered interpretation of the results difficult in these cells, prompting us to use human mesenchymal stem cells (hMSC). Our recent observations have shown that hMSC infected with an EWS-FLI1 containing retrovirus can sustain EWS-FLI-1 expression and display a 20 fold induction of IGF1[17]. Studies by others have shown that downregulation of EWS-FLI-1 expression in ESFT cell lines results in the emergence of an hMSC phenotype [18], supporting the notion that hMSCs may provide an ESFT origin. We therefore used hMSCs to further explore the relationship between ESFT fusion proteins and IGF1. A 1682 nucleotide (nt) region of the human IGF1 promoter upstream of the exon 1 start codon (Ensemble ENSE00001194172) was isolated and ligated to sequences encoding the luciferase reporter gene in the pGL3 plasmid. This promoter region has been shown to be functional or to at least contain functional portions of the promoter in different IGF1 expressing cells, including macrophages [19] and the EWS-FLI-1 expressing Ewing's sarcoma cell line SK-N MC [20]. A 6 fold increase in luciferase activity in SK-N MC cells transfected with the -1682pGL3 construct was observed compared to that in cells bearing a promoterless construct (data not shown). IGF1 promoter analysis using the Genomatix () genome annotation tool "Eldorado" showed that the region from -1682 to +1 contains 2 separate putative promoters upstream of the exon I start codon: GXP79580 from -782 to -64 and GXP641910 from -1664 to -962.
###end p 52
###begin p 53
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Gerald1">[21]</xref>
###xml 650 658 650 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g007">Figure 7</xref>
###xml 706 710 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 790 794 790 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 875 882 875 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t001">Table 1</xref>
###xml 1176 1180 1176 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1294 1302 1294 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g007">Figure 7</xref>
###xml 1447 1451 1447 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1479 1486 1479 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002634-t002">Table 2</xref>
###xml 734 739 <span type="species:ncbi:9606">human</span>
###xml 809 814 <span type="species:ncbi:10090">mouse</span>
MSCs were co-transfected with the -1682pGL3 construct together with either an empty pMSCV or a pMSCV construct containing sequences encoding the EWS-FLI-1, EWS-ERG or FUS-ERG fusion. The EWS-WT1 fusion associated with desmoplastic small round cell tumors (DSRCT,[21]) and a truncated protein composed of the first 262 amino acids of FUS with a short tag were used as controls along with FLI-1 and ERG-1 proteins. A 12-fold increase in luciferase activity was observed in EWS-FLI-1 expressing cells compared to empty pMSCV transfected cells, whereas a 4.5- and a 2.5-fold increase were observed, respectively, in cells expressing EWS-ERG and FUS-ERG (Figure 7). The capacity of the three fusions to mediate IGF1 promoter activation in human MSCs reflected their respective ability to induce IGF1 expression in mouse mesenchymal progenitor cells, as assessed by real time PCR (Table 1). By contrast, luciferase activity in cells expressing EWS-WT1, the FUS (1-262) control protein, FLI-1 or ERG-1 was comparable to that of cells transfected with the empty vector suggesting that neither of the two ets family members nor the EWS and FUS portions alone were able to activate the IGF1 promoter. Consistent with our initial observations, the DBDM did not induce any increase in luciferase activity (Figure 7). The integrity of the DNA binding domain of FLI-1 in the context of the fusion is therefore necessary for EWS-FLI-1 mediated activation of the IGF1 promoter in MPCs and hMSC (Table 2).
###end p 53
###begin title 54
###xml 26 31 <span type="species:ncbi:9606">human</span>
IGF1 promoter activity in human mesenchymal stem cells expressing the three ESFT-associated chimeric proteins EWS-FLI-1, EWS-ERG and FUS-ERG.
###end title 54
###begin p 55
Promoter activity in the presence of the EWS-FLI-1 R340N mutant, the FLI-1 and ERG-1 wild type proteins, the EWS-WT1 fusion and the FUS(1-262)-tag protein are also shown. Luciferase activity is reported as a value relative to that measured in vector transfected cells; error bars represent the S.E.M. of three independent experiments. The significance (p<0.01) of luciferase induction is indicated by an asterisk.
###end p 55
###begin p 56
###xml 14 18 14 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scherf1">[22]</xref>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 399 404 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 855 863 855 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g008">Figure 8</xref>
###xml 160 165 <span type="species:ncbi:9606">human</span>
GEMS analysis [22], used to search for transcription factor binding sites (MatInspector) and sequence models (ModelInspector), of the -1682 to +1 region of the human IGF-1 promoter, revealed the presence of potential binding sites for several different transcription factors, including ets family members, supporting the possibility of direct interaction of Ewing's sarcoma fusion proteins with the IGF-1 promoter. Comparative Genomix analysis, on the other hand, showed no conserved putative ets binding sites in this region, whereas other transcription factor binding sites, such as RFX1, were found to be conserved. To define the relevance of the 2 putative promoter regions GXP79580 and GXP641910, identified by Genomatix analysis, 3 additional luciferase fusion plasmids were generated by restriction enzyme cleavage and ligation to the pGL3 vector (Figure 8 A). Constructs -1098pGL3 and -913pGL3, generated respectively by XhoI/HindIII, and KpnI/HindIII digestion, included the entire GXP79580 promoter, a short sequence of GXP641910 being included in the -1098pGL3 construct. The -673pGL3 plasmid, obtained by AvaI/HindIII digestion, contained only part of the GXP79580 promoter.
###end p 56
###begin title 57
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Schematic representation of IGF1 promoter fragments cloned into the pGL3 basic vector (A) and the corresponding luciferase activity (B) in human mesenchymal stem cells expressing EWS-FLI-1.
###end title 57
###begin p 58
###xml 220 228 220 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002634-g006">Figure 6</xref>
Restriction sites used for cloning are indicated. The exon 1 start codon, putative promoter regions GXP79580 and GXP641910 according to GEM analysis (Genomatix) are shown. Levels of luciferase activity, calculated as in Figure 6, are normalized to values obtained with the -1682 construct which was arbitrarily set to 100%. Error bars represent the S.E.M. of three independent experiments.
###end p 58
###begin p 59
###xml 33 38 <span type="species:ncbi:9606">human</span>
Luciferase activity, measured in human mesenchymal stem cells transfected with an EWS-FLI-1 containing plasmid together with the -1098pGL3 or the -913pGL3 construct, was similar, a 20% reduction of activity being observed in both cases compared to cells into which the entire promoter region -1682 had been introduced. A more robust reduction of activity (70%) was observed when the -673pGL3 construct was introduced.
###end p 59
###begin p 60
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
###xml 489 494 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF-1</italic>
Taken together these data suggest that both GXP79580 and GXP641910 regions contribute to EWS-FLI-1 mediated IGF1 promoter activity, although a more substantial contribution is made by the GXP79580 region. The observed difference in contribution could be explained by the loss of potential binding sites for different transcription factors within this region. Although ets binding sites are plausible candidates for EWS/FLI-1 mediated IGF-1 promoter activation, other sequences relevant to IGF-1 promoter activity could be present in the deleted segments. Among many other binding sites lost in the -673 construct were an E-box, a STAT binding site which forms a sequence model (Genomatix modelInspector) together with an ets binding site, and a Myc associated zinc finger binding site (MAZF). Mutagenesis experiments to define the role of different potential ets and other transcription factor binding sites in the regulation of IGF-1 expression are ongoing.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 596 599 596 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Helman1">[1]</xref>
###xml 601 604 601 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi1">[2]</xref>
###xml 606 609 606 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi2">[4]</xref>
###xml 611 615 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Welford1">[12]</xref>
###xml 853 858 <span type="species:ncbi:10090">mouse</span>
The distinguishing feature of Ewing's sarcoma is the expression of an aberrant transcription factor encoded by a fusion gene resulting from a non-random chromosomal translocation. In all cases the fusion protein is composed of the amino terminal portion of a TET family member that provides a potent transactivating domain and the DNA binding domain of one of several possible ets family members. In more than 99% of cases, the TET family member is EWS and in 85-90% of cases the ets family member is FLI-1. EWS is fused to ERG in 5-10% of cases whereas FUS-ERG is found in less than 1% of cases [1], [2], [4], [12]. The difference in frequency of association of the fusion proteins with ESFT is currently unexplained, and could conceivably reflect the relative frequency of the corresponding chromosomal breaks. However, our present observations using mouse MPCs suggest that primary mesenchymal stem cells display a markedly different degree of permissiveness for the three fusion proteins. Whereas expression of EWS-FLI-1 was tolerated in all of the cell batches tested, expression of EWS-ERG was restricted to a fraction of the batches while stable expression of FUS-ERG could not be achieved. The observed differential permissiveness correlates with the relative frequency at which each fusion accompanies ESFT cases, suggesting distinct windows of opportunity for the different fusion proteins to display their putative transforming properties in MPCs.
###end p 62
###begin p 63
Mechanisms whereby MPCs restrict expression of EWS-ERG and FUS-ERG remain to be elucidated. Whereas in some cases the specific RNA was not detectable or appeared degraded, in others protein expression could not be detected despite maintenance of transcripts of appropriate length. It is conceivable that discrete stages of MPC differentiation may account for the observed differences in permissiveness. Alternatively, MPCs may be composed of functionally heterogeneous cell subsets that cannot be distinguished on the basis of the restricted number of phenotypic markers used to characterize them. A plausible scenario may be that a majority of these putative subsets display a milieu that is favourable for EWS-FLI-1 expression and function, whereas only rare subsets may tolerate expression of FUS-ERG. Thus, the composition or differentiation stage of MPC populations may determine whether or not expression of ESFT-associated fusion proteins other than EWS-FLI-1 may be sustained.
###end p 63
###begin p 64
The observed difference in permissiveness for fusion protein expression could not be attributed to functional differences among MPC batches because the same batches were used for expression of all of the contructs.
###end p 64
###begin p 65
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARF</sup>
###xml 119 122 119 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-CastilleroTrejo1">[23]</xref>
Although EWS-FLI-1 has been shown to have the capacity to transform primary MPCs that express functional p53 and p19ARF[8], EWS-FLI-1 expression and transforming potential in primary unsorted bone marrow cells were found to be facilitated by inactivating TP53 mutations [23]. Alterations in signaling pathways relevant to oncogenesis may therefore provide at least one mechanism that renders primary cells permissive for ESFT-associated fusion protein expression and susceptible to the corresponding transforming properties.
###end p 65
###begin p 66
###xml 530 534 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Araya1">[24]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Arvand1">[25]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Gascoyne1">[26]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Knoop1">[27]</xref>
###xml 554 558 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Yang1">[28]</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Zhang1">[29]</xref>
###xml 1300 1305 1300 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1.</italic>
Interestingly, FLI-1 and ERG-1 displayed higher potential target gene similarity in the context of EWS-associated fusion proteins than alone. It is possible that several common FLI-1 and ERG-1 candidate targets are undetected because of the weakness of the intrinsic transactivation domain of the two transcription factors. The potency of EWS transactivation may provide a mechanism to unmask such putative targets. The ability of EWS to interact with numerous proteins implicated in transcriptional regulation and RNA processing [24], [25], [26], [27], [28], [29] may supply an alternative explanation. Thus, it is possible that a combination of EWS and its binding partners confer upon FLI-1 and ERG-1 the ability to induce expression of common genes. Of the fraction of induced and repressed transcripts that were common to the three fusion proteins, most are not known to be directly implicated in transformation, and it is possible that the three fusion proteins use distinct mechanisms to transform primary cells, resulting nevertheless in tumors with an indistinguishable phenotype as assessed by conventional histology and immunohistochemistry. One potentially important functional similarity among the fusion proteins in the context of ESFT pathogenesis, however, is their ability to induce IGF1.
###end p 66
###begin p 67
###xml 118 121 118 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 200 212 200 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP3</italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP5</italic>
###xml 298 301 298 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scotlandi1">[30]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scotlandi2">[31]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scotlandi3">[32]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Toretsky1">[33]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scotlandi2">[31]</xref>
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scotlandi3">[32]</xref>
###xml 597 609 597 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1, IGFBP3</italic>
###xml 614 620 614 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP5</italic>
###xml 730 734 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 739 745 739 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP5</italic>
###xml 987 991 987 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1008 1015 1008 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1063 1067 1063 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 1176 1180 1176 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 1122 1127 <span type="species:ncbi:9606">human</span>
Recently, EWS-FLI1 was shown to transform MPCs and produce tumors with an ESFT-like phenotype in immunodeficient mice [8]. Three potentially relevant genes that were found to be strongly induced were IGF1, IGFBP3 and IGFBP5. IGF-1 is believed to play a critical role in ESFT growth and development [8], [30], [31], [32]. Transformation of NIH3T3 fibroblasts by EWS-FLI-1 requires expression of IGF-1R [33] and blockade of the receptor using antibodies [31] or small molecule receptor tyrosine kinase (RTK) inhibitors [8], [32] strongly inhibits ESFT cell growth. The present results indicate that IGF1, IGFBP3 and IGFBP5 are induced by all of the fusion proteins tested but not by FLI-1 and ERG-1 alone. Importantly, induction of IGF1 and IGFBP5 requires integrity of the DBD of FLI-1 within the fusion protein as demonstrated by the inability of the DBDM to induce either molecule. Quantitative RT-PCR results from chromatin immunoprecipitates argue that EWS-FLI-1 interaction with the IGF1 promoter occurs in vivo. The observations that EWS-FLI-1 activates the IGF1 promoter as assessed by luciferase reporter assays in human MSCs provide further support to the notion that IGF1 is a target of EWS-FLI-1.
###end p 67
###begin p 68
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Prieur1">[34]</xref>
By contrast, the DBDM could induce IGFBP3 suggesting that in MPCs EWS-FLI-1 does not require integrity of the DBD for IGFBP3 upregulation. The observation that IGFBP3 was induced in a non-DBD-dependent manner by EWS-FLI-1 in MPCs in apparent contrast to the recent report that IGFBP3 is a direct target of EWS-FLI-1 which is down regulated as a result of EWS-FLI-1 expression in an ESFT cell line [34]. These contrasting results may be explained, in part, by cell state differences. ESFT cell lines reflect late stage tumor progression where the effect of EWS-FLI-1 may be modulated by a variety tumor stage-associated factors. The effect of EWS-FLI-1 and the other fusion proteins on MPCs, on the other hand, was evaluated in primary cells at an early time point following expression, prior to transformation and tumor development.
###end p 68
###begin p 69
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
Growth hormone induces IGF-1 and the robust growth hormone spurt during puberty may help create favorable conditions for the initial development of ESFT from mesenchymal stem cells harboring the appropriate chromosomal translocations and expressing the corresponding fusion proteins. Subsequent maintenance of tumor growth may require tumor cell-autonomous IGF-1 production and IGF1 induction may provide one mechanism whereby EWS-FLI-1 and its ESFT-associated relatives ensure tumor growth and progression.
###end p 69
###begin title 70
Materials and Methods
###end title 70
###begin title 71
Mesenchymal stem cells and cell lines
###end title 71
###begin p 72
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Jiang1">[35]</xref>
###xml 475 478 475 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 322 327 <span type="species:ncbi:9606">human</span>
Mouse mesenchymal progenitor cells (MPCs) were isolated from bone marrow of adult C57BL/6, wild type mice according to the methods described in [35], and cultured on fibronectin-coated plates (Sigma) in medium containing 2% dialyzed FCS (Sigma), 10 ng/ml EGF (Sigma), 10ng/ml PDGF-BB (R&D Systems) and 10ng/ml recombinant human leukemia inhibitory factor (Chemicon). Mesenchymal stem cells markers expression and differentiation assays were performed as previously described [8].
###end p 72
###begin p 73
###xml 67 71 67 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Suva1">[36]</xref>
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Suva2">[37]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Suva1">[36]</xref>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Suva2">[37]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Human mesenchymal stem cells were obtained as previously described [36], [37] from femoral head bone marrow of patients undergoing total hip replacement according to the guidelines of the ethical committee protocol 01-172 and after informed consent of the patients. MSCs were cultured at low confluence in IMDM, 10% FCS, 10 ng/ml PDGF-BB (PeProtechEC, London,UK) and were tested for multilineage differentiation into adipocytes, chondrocytes and osteoblasts [36], [37]. The SK-N-MC cell line was from ATCC (Rockville, MD).
###end p 73
###begin title 74
Cell cycle analysis
###end title 74
###begin p 75
DNA content and cell cycle analysis were performed by flow cytometry. Cells were centrifuged, and the pellets were gently resuspended in 1.5mL hypotonic propidium iodide solution (PI, 50 microg/mL in 0.1% sodium citrate plus 0.1% Triton X-100; Sigma). The tubes were kept at 4degreesC in the dark overnight. The PI-fluorescence of individual nuclei was measured by flow cytometry using standard FACScan equipment (Becton Dickinson, Mountain View, CA).
###end p 75
###begin title 76
Constructs and cDNA Cloning
###end title 76
###begin p 77
A cDNA clone encoding the type 2 EWS-FLI-1 fusion protein was amplified from the SK-N-MC Ewing sarcoma cell line by RT-PCR. The amplified fragment carrying an in frame v5 tag at the 3'extremity was digested with XhoI and Hpa I and inserted into the pMSCV Puro retroviral expression vector (BD Biosciences Clontech, Palo Alto, CA).
###end p 77
###begin p 78
The EWS-FLI-1 R340N DBDM was amplified by PCR using the wt sequence as template, with the following primers:
###end p 78
###begin p 79
hEWS forward XhoI:
###end p 79
###begin p 80
###xml 0 39 0 39 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CCGCTCGAGCCACCATGGCGTCCACGGATTACAG 3&#8242;</named-content>
5'CCGCTCGAGCCACCATGGCGTCCACGGATTACAG 3';
###end p 80
###begin p 81
hFLI-1 reverse R340N:
###end p 81
###begin p 82
###xml 0 42 0 42 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; ATCATAGTAATAATTGAGGGCCCGGCTCAGCTTGTC 3&#8242;</named-content>
5' ATCATAGTAATAATTGAGGGCCCGGCTCAGCTTGTC 3';
###end p 82
###begin p 83
hFLI-1 forward R340N:
###end p 83
###begin p 84
###xml 0 42 0 42 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CGACAAGCTGAGCCGGGCCCTCAATTATTACTATGA 3&#8242;</named-content>
5' CGACAAGCTGAGCCGGGCCCTCAATTATTACTATGA 3';
###end p 84
###begin p 85
V5 reverse Hpa I (including a stop codon):
###end p 85
###begin p 86
###xml 0 57 0 57 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GTTAACTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC 3&#8242;</named-content>
5' GTTAACTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC 3'.
###end p 86
###begin p 87
The amplified fragment was XhoI-HpaI-digested and inserted into the pMSCVPuro retroviral vector.
###end p 87
###begin p 88
EWS-ERG and ERG-1 fragments were amplified from surgically resected Ewing's sarcoma tissue by RT-PCR.
###end p 88
###begin p 89
###xml 368 373 <span type="species:ncbi:9606">Human</span>
###xml 488 493 <span type="species:ncbi:9606">human</span>
###xml 647 652 <span type="species:ncbi:9606">human</span>
###xml 777 782 <span type="species:ncbi:9606">human</span>
Amplified fragments, carrying a BglII restriction site at the 5'end were inserted, using the pcDNA3.1/V5-HisTOPO TA cloning kit (Invitrogen, Carlsbad, CA), into the corresponding expression vector in frame with the V5 epitope tag. The EWS-ERG-v5 and the ERG-1-v5 fragments were digested with BglII and PmeI and inserted into the BglII/HpaI-digested pMSCV Puro vector. Human FLI-1 cDNA was amplified from hMSC RNA and inserted into EcoRI/XhoI-digested pMSCV Puro. cDNA clones encoding the human FUS-ERG AML and FUS-ERG ESFT fusions were obtained by PCR and inserted into BglII/HpaI-digested pMSCV Puro. Fragments encoding exons 1-7 or exons 1-6 of human TLS/FUS, amplified from the EST clone IMAGE:3345294, and a fragment encoding the C-terminal portion, starting at exon 9, of human ERG, amplified from the EWS-ERG-v5 clone, were used in the PCR reactions.
###end p 89
###begin p 90
The primer sequences were:
###end p 90
###begin p 91
###xml 24 77 24 77 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GTTAGGGATAGGCTTACCTTCGAACCGCGGGCCGTAGTAAGTGCCCAG 3&#8242;</named-content>
External ERG-v5-reverse 5'GTTAGGGATAGGCTTACCTTCGAACCGCGGGCCGTAGTAAGTGCCCAG 3'
###end p 91
###begin p 92
External BglII FUS forward
###end p 92
###begin p 93
###xml 0 43 0 43 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GGAAGATCTTCCCCACCATGGCCTCAAACGATTATACC 3&#8242;</named-content>
5'GGAAGATCTTCCCCACCATGGCCTCAAACGATTATACC 3'
###end p 93
###begin p 94
Internal for FUS-ERG AML:
###end p 94
###begin p 95
###xml 7 59 7 59 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GCTTCAATAAATTTGGTGGCAGTGGCCAGATCCAGCTTTGGCAGTTCC3&#8242;</named-content>
Forward5'GCTTCAATAAATTTGGTGGCAGTGGCCAGATCCAGCTTTGGCAGTTCC3'
###end p 95
###begin p 96
###xml 8 55 8 55 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;AGCTGGATCTGGCCACTGCCACCAAATTTATTGAAGCCACCAC3&#8242;</named-content>
Reverse 5'AGCTGGATCTGGCCACTGCCACCAAATTTATTGAAGCCACCAC3'
###end p 96
###begin p 97
Internal for FUS-ERG ESFT:
###end p 97
###begin p 98
###xml 8 50 8 50 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GCCGTGGAGGCAGAGGCAGTGGCCAGATCCAGCTTTG 3&#8242;</named-content>
Forward 5'GCCGTGGAGGCAGAGGCAGTGGCCAGATCCAGCTTTG 3'
###end p 98
###begin p 99
###xml 8 55 8 55 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CAAAGCTGGATCTGGCCACTGCCTCTGCCTCCACGGCCACCT 3&#8242;</named-content>
Reverse 5'CAAAGCTGGATCTGGCCACTGCCTCTGCCTCCACGGCCACCT 3'
###end p 99
###begin p 100
###xml 57 62 <span type="species:ncbi:9606">human</span>
A cDNA control encoding the first 262 amino acids of the human TLS/FUS protein followed by a tail of 54 random amino acids was obtained by PCR and inserted into pMSCV Puro. The 54 random amino acid tail displayed no homology in a BLAST search and contained none of the motifs present in the ERG-1 or FLI-1 proteins as assessed by the SMART- Simple Modular Architecture Research Tool []. All constructs were sequence-verified.
###end p 100
###begin title 101
Retrovirus generation and infection
###end title 101
###begin p 102
Expression of EWS-FLI-1, EWS-ERG, FUS-ERG (AML), FUS-ERG (ESFT) , ERG-1 and FLI-1 in MPCs was achieved using the Retroviral Gene Transfer and Expression (BD Biosciences Clontech), according to the manufacturer's recommendations. Infected cells were selected in 1.5 microg/ml puromycin for a maximum of 14 days.
###end p 102
###begin title 103
RNA and genomic DNA extraction and Reverse Transcription PCR
###end title 103
###begin p 104
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany) and genomic DNA was isolated using a DNeasy Tissue Kit (Qiagen) according to the manufacturer's recommendations. RT-PCR was performed using Super Script one step RT-PCR with the platinum Taq kit (Invitrogen, Carlsbad, CA).
###end p 104
###begin title 105
Western blot analysis
###end title 105
###begin p 106
###xml 253 258 <span type="species:ncbi:10090">mouse</span>
###xml 297 302 <span type="species:ncbi:10090">mouse</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 393 398 <span type="species:ncbi:10090">mouse</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 445 449 <span type="species:ncbi:9925">goat</span>
###xml 455 460 <span type="species:ncbi:10090">mouse</span>
Cell lysis, SDS-PAGE and blotting were done according to standard procedures and immunodetection was performed using chemoluminescent substrate kits from Amersham according to the manufacturer's recommendations. Primary antibodies used were: monoclonal mouse anti-V5epitope antibody (Invitrogen), mouse anti human FLI-1 monoclonal antibody (G146-222 BD- Pharmingen, San Diego, CA), monoclonal mouse anti-actin (Sigma) and mouse IgG (Sigma). The goat anti-mouse HRP conjugated secondary antibody was from Amersham. Densitometric analysis was performed using the public domain image processing and analysis program NIH image J ().
###end p 106
###begin title 107
cDNA array hybridization and cDNA array analysis
###end title 107
###begin p 108
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
###xml 707 710 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Riggi3">[8]</xref>
For each comparison 3 independently isolated MPC populations were used and 3 independent infections were performed. Total RNA was extracted at 36 hours following infection. The quality of RNA was verified by an Agilent RNA 600 nanoassay and by measuring the 260/280 absorbance ratio. Quality-tested total RNA was amplified using the RiboAmp RNA Amplification Kit (Arcturus, Moutainview, CA) and processed using a reverse transcription based method of label incorporation to yield labeled cDNA as previously described [8]. Following hybridization and washing, microarrays were imaged using a DNA microarray scanner (agilent technologies) and array analysis and quality control were performed as described in [8].
###end p 108
###begin title 109
Statistical analysis of the expression data
###end title 109
###begin p 110
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Breitling1">[38]</xref>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Hong1">[39]</xref>
RNA derived from EWS-FLI-1, EWS-ERG, FUS-ERG (AML), FUS-ERG (ESFT), ERG-1 and FLI-1 expressing MPC populations were all subjected to microarray analysis; five m17k microarrays (among which 2 were dye swaps) were performed for each population, comparing cells expressing the protein of interest with the corresponding empty vector control cells. Differentially expressed genes were then identified with the rank product method [38] as implemented in the "RankProd" Bioconductor package [39]. We retained for further analysis the clones identified as differentially expressed with a false discovery rate of 5%. The statistical significance of the overlap between differentially expressed genes in different translocations was evaluated with Fisher's exact test.
###end p 110
###begin title 111
Real time quantitative RT-PCR
###end title 111
###begin p 112
###xml 283 286 <span type="species:ncbi:9606">Man</span>
###xml 336 339 <span type="species:ncbi:9606">Man</span>
cDNA was obtained using an M-MLV reverse transcriptase and RNAse H minus (Promega). Typically 500 ng of template total RNA and 250 ng of random hexamers were used per reaction. Real time-PCR amplification was performed in an ABI Prism 7700 instrument (Applied Biosystems), using Taq Man Universal PCR mastermix and Assays-On-Demand Taq Man probes for IGF1, IGFBP5, IGFBP3, SFRP4, DKK2, DCN, MT2 and MMP3.
###end p 112
###begin p 113
For real time quantitation of CITED1, DHH, PODXL, KRT1-19, CDH5, ENO3 and DKK3 RNAs, the Universal Probe Library system (Roche Rotkreuz, Switzerland) was used and primers were designed according to the ProbeFinder software ().
###end p 113
###begin p 114
The following primers were designed:
###end p 114
###begin p 115
ENO3:
###end p 115
###begin p 116
###xml 7 29 7 29 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CCGGGAAATCCTGGACTC3&#8242;</named-content>
forward5'CCGGGAAATCCTGGACTC3'
###end p 116
###begin p 117
###xml 8 30 8 30 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CAGCTGCTCGGAATCGAC3&#8242;</named-content>
reverse 5'CAGCTGCTCGGAATCGAC3'
###end p 117
###begin p 118
CDH5:
###end p 118
###begin p 119
###xml 7 32 7 32 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;TCACCTTCTGTGAGGAGATGG3&#8242;</named-content>
forward5'TCACCTTCTGTGAGGAGATGG3'
###end p 119
###begin p 120
###xml 8 36 8 36 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GATGATCAGCAAGGTAATCACTGT3&#8242;</named-content>
reverse 5'GATGATCAGCAAGGTAATCACTGT3'
###end p 120
###begin p 121
PODXL:
###end p 121
###begin p 122
###xml 7 31 7 31 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GGATCTCCCAGAGGAAGGAC3&#8242;</named-content>
forward5'GGATCTCCCAGAGGAAGGAC3'
###end p 122
###begin p 123
###xml 8 32 8 32 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CAAGGTTGGGTTGTCATGGT3&#8242;</named-content>
reverse 5'CAAGGTTGGGTTGTCATGGT3'
###end p 123
###begin p 124
DKK3:
###end p 124
###begin p 125
###xml 7 34 7 34 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CTCAATGAGATGTTTCGAGAGGT3&#8242;</named-content>
forward5'CTCAATGAGATGTTTCGAGAGGT3'
###end p 125
###begin p 126
###xml 8 33 8 33 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CTTCTTCCGCCTCCATCTC 3&#8242;</named-content>
reverse 5' CTTCTTCCGCCTCCATCTC 3'
###end p 126
###begin p 127
CITED1:
###end p 127
###begin p 128
###xml 7 30 7 30 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CTAGGTCGCTTCGTCCGTA3&#8242;</named-content>
forward5'CTAGGTCGCTTCGTCCGTA3'
###end p 128
###begin p 129
###xml 8 30 8 30 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;AGCTGGGCCTGTTGGTCT3&#8242;</named-content>
reverse 5'AGCTGGGCCTGTTGGTCT3'
###end p 129
###begin p 130
KRT1-19:
###end p 130
###begin p 131
###xml 7 31 7 31 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;TGGAGATGCAGATTGAGAGC3&#8242;</named-content>
forward5'TGGAGATGCAGATTGAGAGC3'
###end p 131
###begin p 132
###xml 8 32 8 32 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;TCCTCAGGGCAGTAATTTCC3&#8242;</named-content>
reverse 5'TCCTCAGGGCAGTAATTTCC3'
###end p 132
###begin p 133
For GAPDH amplification, rodent GAPDH control reagent (Applied Biosystems) was used. Relative quantitation of target, normalized with an endogenous control (GAPDH), was performed using a comparative Ct method (Applied Biosystems).
###end p 133
###begin title 134
IGF1 promoter analysis and cloning
###end title 134
###begin p 135
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002634-Scherf1">[22]</xref>
In silico IGF1 promoter analysis was performed using the Genomatix () genome annotation tool "Eldorado". Specifically, GEMS analysis was used with both MatInspector and ModelInspector tools to search for putative transcription factor binding sites and sequence models [22]. Comparative genomix was also used.
###end p 135
###begin p 136
###xml 134 172 134 172 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CCCAAGCTTGGGTGCTTCTGAAGTACAAAGTCTG3&#8242;</named-content>
###xml 177 219 177 219 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GAAGATCTTCAAATGTTGCTGAACATAGTGCACCATTG3&#8242;</named-content>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human IGF1 promoter sequence from position -1682 to +1 (start codon on exon 1) was amplified from hMSC genomic DNA using primers: 5'CCCAAGCTTGGGTGCTTCTGAAGTACAAAGTCTG3' and 5'GAAGATCTTCAAATGTTGCTGAACATAGTGCACCATTG3'.
###end p 136
###begin p 137
The amplified fragment was ligated into the BglII and HindIII cloning sites of the pGL3-basic vector (promega) and sequence-verified. Smaller IGF1 promoter fragments (-1098, -913 and -673) were obtained from the -1682pGL3 construct by digestion and re-ligated into the pGL3-basic vector. Restriction enzyme digestion was as follows: HindIII/XhoI to obtain the -1098 fragment, : HindIII/KpnI to obtain the -913 fragment and HindIII/AvaI to obtain the -673 fragment.
###end p 137
###begin title 138
Transient transfection and luciferase assays
###end title 138
###begin p 139
###xml 230 234 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 618 622 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
###xml 770 774 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
2 microg of empty pMSCV plasmid or pMSCV encoding human FLI-1, ERG-1, EWS-FLI-1, EWS-ERG, FUS-ERG, EWS-WT1 and the EWS-FLI-1 R340N DBD mutant were introduced by nucleofection along with 2 microg of a pGL3 basic vector or the pGL3-IGF1 promoter construct (-1682pGL3) into freshly isolated human mesenchymal stem cells using a nucleofector II device and the appropriate solution according to manufacturer's recommendation (Amaxa GmbH, Koeln, Germany). For promoter region analysis, 2 microg of pMSCV encoding human EWS-FLI-1 were introduced by nucleofection along with 2 microg of a pGL3 basic vector or one of the pGL3-IGF1 promoter constructs. General transfection efficiency was controlled using a pMAX-GFP control vector (AMAXA) or a pGL3 promoter vector containing a SV40 promoter. A 75% efficiency was calculated in MSCs using nucleofection. Transfection efficiency for both fusion proteins and luciferase reporter plasmid was more specifically controlled by PCR or RT-PCR performed on RNA or DNA using primers specific for either luciferase or each of the fusion genes. Luciferase activity was measured 48 hours later on cleared cell lysates using the luciferase assay system (Promega) according to manufacturer's recommendations. 3 independent experiments were performed using 2 different batches of hMSCs. Reporter luciferase activity was measured in triplicate, mean values were corrected for total cell number and reported as relative values to vector transfected cells. Total protein normalization was not possible due to the presence in the luciferase kit lysis buffer of components that disrupt common total protein measurement assays. Nevertheless parallel experiments were performed with fractions of the same cell populations lysed in appropriate buffer to control the correspondence between cell number and total proteins.
###end p 139
###begin p 140
Statistical significance was determined with a 2 sided t-test on the logarithm of the relative activity.
###end p 140
###begin title 141
Chromatin immunoprecipitation
###end title 141
###begin p 142
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
###xml 571 577 <span type="species:ncbi:9986">rabbit</span>
###xml 956 961 <span type="species:ncbi:10090">mouse</span>
ChIP was performed according to the Abcam protocol (Abcam, Cambridge, UK). Briefly 1x107 mouse MPCs expressing either EWS-FLI-1, EWS-FLI-1 R340N mutant or an empty pMSCV vector, were cross-linked with 1% folmaldehyde for 10 min. After addition of 0.125 M glycine and washing in cold PBS, cells were lysed and the chromatin fraction was sheared to roughly 700bp fragments by sonication. About 1/15 of the lysate was digested with proteinase K, phenol chloroform extracted, ethanol-precipitated and stored as input DNA. Immunoprecipitation was performed using a chip-grade rabbit polyclonal anti V5 antibody (Abcam) and herring sperm DNA blocked protein A-sepharose beads. The cross linkage was reversed using proteinase K and the DNA purified by phenol/chloroform extraction and ethanol precipitation. Quantitative PCR on the immunoprecipitate and on input DNA was performed on a ABI Prism 7700 instrument (Applied Biosystems). Primers complementary to the mouse IGF1 promoter region from -2754 to -2683 and control primers spanning a region 14000 bp upstream of the IGF1 exon 1 start codon were designed using the Assay Design Center ProbeFinder (Roche) and were as follows:
###end p 142
###begin p 143
###xml 9 34 9 34 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; TGCCTGGCAACTAGGACAA 3&#8242;</named-content>
Forward: 5' TGCCTGGCAACTAGGACAA 3'
###end p 143
###begin p 144
###xml 9 35 9 35 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GATCGAAAGGCAGCTCTCAG 3&#8242;</named-content>
Reverse: 5' GATCGAAAGGCAGCTCTCAG 3'
###end p 144
###begin p 145
###xml 17 44 17 44 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; AGGTCCAAAAGTTGCATCAGA 3&#8242;</named-content>
Control Forward: 5' AGGTCCAAAAGTTGCATCAGA 3'
###end p 145
###begin p 146
###xml 17 43 17 43 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CGAGACTCCCTGCCTTAAAA 3&#8242;</named-content>
Control Reverse: 5' CGAGACTCCCTGCCTTAAAA 3'
###end p 146
###begin p 147
###xml 25 31 <span type="species:ncbi:10090">murine</span>
Primers complementary to murine GAPDH DNA were used as the Input control.
###end p 147
###begin title 148
Supporting Information
###end title 148
###begin p 149
(0.38 MB TIF)
###end p 149
###begin p 150
Click here for additional data file.
###end p 150
###begin p 151
(0.69 MB DOC)
###end p 151
###begin p 152
Click here for additional data file.
###end p 152
###begin p 153
(0.06 MB DOC)
###end p 153
###begin p 154
Click here for additional data file.
###end p 154
###begin p 155
(0.81 MB XLS)
###end p 155
###begin p 156
Click here for additional data file.
###end p 156
###begin p 157
(0.08 MB XLS)
###end p 157
###begin p 158
Click here for additional data file.
###end p 158
###begin p 159
We thank Carlo Fusco and Marina Bacac for helpful comments, Prof. Pierre Hoffmeyer for fruitful collaboration and Karine Baumer for technical support. All animal experiments were performed in compliance with the regulations on animal experimentation of the Canton de Vaud, permit #1477.1
###end p 159
###begin title 160
References
###end title 160
###begin article-title 161
Mechanisms of sarcoma development.
###end article-title 161
###begin article-title 162
The Biology of Ewing sarcoma.
###end article-title 162
###begin article-title 163
###xml 81 86 <span type="species:ncbi:9606">human</span>
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.
###end article-title 163
###begin article-title 164
Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.
###end article-title 164
###begin article-title 165
Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.
###end article-title 165
###begin article-title 166
Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation.
###end article-title 166
###begin article-title 167
###xml 89 94 <span type="species:ncbi:9606">human</span>
The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.
###end article-title 167
###begin article-title 168
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.
###end article-title 168
###begin article-title 169
EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.
###end article-title 169
###begin article-title 170
EWS/FLI function varies in different cellular backgrounds.
###end article-title 170
###begin article-title 171
FUS/ERG gene fusions in Ewing's tumors.
###end article-title 171
###begin article-title 172
DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis.
###end article-title 172
###begin article-title 173
Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
###end article-title 173
###begin article-title 174
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.
###end article-title 174
###begin article-title 175
###xml 29 34 <span type="species:ncbi:9606">human</span>
Gene expression profiling of human sarcomas: insights into sarcoma biology.
###end article-title 175
###begin article-title 176
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
Developmental regulation of the mouse IGF-I exon 1 promoter region by calcineurin activation of NFAT in skeletal muscle.
###end article-title 176
###begin article-title 177
###xml 78 83 <span type="species:ncbi:9606">human</span>
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
###end article-title 177
###begin article-title 178
Mesenchymal stem cell features of Ewing tumors.
###end article-title 178
###begin article-title 179
Transcription of macrophage IGF-I exon 1 is positively regulated by the 5'-untranslated region and negatively regulated by the 5'-flanking region.
###end article-title 179
###begin article-title 180
###xml 77 82 <span type="species:ncbi:9606">human</span>
Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I.
###end article-title 180
###begin article-title 181
The EWS-WT1 gene fusion in desmoplastic small round cell tumor.
###end article-title 181
###begin article-title 182
Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach.
###end article-title 182
###begin article-title 183
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
###end article-title 183
###begin article-title 184
Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription.
###end article-title 184
###begin article-title 185
Biology of EWS/ETS fusions in Ewing's family tumors.
###end article-title 185
###begin article-title 186
The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1.
###end article-title 186
###begin article-title 187
The splicing factor U1C represses EWS/FLI-mediated transactivation.
###end article-title 187
###begin article-title 188
EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.
###end article-title 188
###begin article-title 189
The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription.
###end article-title 189
###begin article-title 190
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
###end article-title 190
###begin article-title 191
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
###end article-title 191
###begin article-title 192
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
###end article-title 192
###begin article-title 193
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
###end article-title 193
###begin article-title 194
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
###end article-title 194
###begin article-title 195
Pluripotency of mesenchymal stem cells derived from adult marrow.
###end article-title 195
###begin article-title 196
###xml 18 23 <span type="species:ncbi:9606">human</span>
Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells.
###end article-title 196
###begin article-title 197
###xml 19 24 <span type="species:ncbi:9606">human</span>
In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them.
###end article-title 197
###begin article-title 198
Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments.
###end article-title 198
###begin article-title 199
RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis.
###end article-title 199
###begin p 200
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 200
###begin p 201
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by SNSF grant 3100A0-105833, OCS grant 01656-02-2005 and the NCCR Molecular Oncology.
###end p 201

